JP2001504802A - 非水性プロトン性ペプチド配合物 - Google Patents
非水性プロトン性ペプチド配合物Info
- Publication number
- JP2001504802A JP2001504802A JP50421898A JP50421898A JP2001504802A JP 2001504802 A JP2001504802 A JP 2001504802A JP 50421898 A JP50421898 A JP 50421898A JP 50421898 A JP50421898 A JP 50421898A JP 2001504802 A JP2001504802 A JP 2001504802A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- compound
- leuprolide
- peptide
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.a)少なくとも1種のペプチド化合物;および b)少なくとも1種の非水性プロトン性溶媒; を含む、ペプチド化合物の安定な非水性配合物。 2.少なくとも約10%(重量/重量)のペプチド化合物を含む、請求項1の 配合物。 3.少なくとも約30%(重量/重量)のペプチド化合物を含む、請求項1の 配合物。 4.前記ペプチド化合物がLHRH−関連化合物である、請求項1の配合物。 5.前記ペブチド化合物がロイプロリド、LHRH、ナファレリンおよびゴセ レリンからなる群から選ばれる、請求項4の配合物。 6.照射線照射後に安定である、請求項1の配合物。 7.少なくとも3か月間37℃で安定である、請求項1の配合物。 8.少なくとも1年間37℃で安定である、請求項1の配合物。 9.植え込み可能な医薬送り出し器具において使用するために適合されている 、請求項1の配合物。 10.前記少なくとも1種の非水性プロトン性溶媒が、PG、PEGおよびグ リセロールからなる群から選ばれる、請求項1の配合物。 11.ゲルを形成する、請求項1の配合物。 12.少なくとも1種の非水性極性非プロトン性溶媒をさらに含む、請求項1 の配合物。 13.前記極性非プロトン性溶媒がDMSOまたはDMFである請求項12の 配合物。 14.さらに水を含む、請求項1の配合物。 15.賦形剤、界面活性剤、溶解化剤および保存料からなる群から選ばれる、 少なくとも1種をさらに含む、請求項1の配合物。 16.PGまたはPEGまたはそれらの混合物中の約30%〜約50%(重量 /重量)のLHRH−関連化合物酢酸ロイプロリドから本質的になる、請求項1 の配合物。 17.少なくとも1種の非水性プロトン性溶媒中に少なくとも1種のペプチド 化合物を溶解することからなる、請求項1の安定な非水性配合物の製造方法。 18.少なくとも10%(重量/重量)のペプチド化合物が溶解される、請求 項17の方法。 19.少なくとも30%(重量/重量)のペプチド化合物が溶解される、請求 項17の方法。 20.前記ペプチド化合物が、LHRH−関連化合物である、請求項17の方 法。 21.前記ペプチド化合物がロイプロリド、LHRH、ナファレリンおよびゴ セレリンからなる群から選ばれる、請求項20の方法。 22.賦形剤、界面活性剤、溶解化剤およ保存料からなる群から選ばれる少な くとも1種を加える工程をさらに含む、請求項17の方法。 23.少なくとも1種の非水性極性非プロトン性溶媒を加える工程をさらに含 む、請求項17の方法。 24.前記極性非プロトン性溶媒がDMSOまたはDMFである、請求項23 の方法。 25.水を加える工程をさらに含む、請求項17の方法。 26.前記少なくとも1種の非水性プロトン性溶媒がPG、PEGおよびグリ セロールからなる群から選ばれる、請求項17の方法。 27.PGまたはPEGあるいはそれらの混合物中に約30%〜約50%(重 量/重量)のLHRH−関連化合物酢酸ロイプロリドが溶解される、請求項17 の方法。 28.請求項1の配合物の有効量を下記の患者に投与することからなる、ペプ チド化合物の投与により緩和されることが出来る症状を患っている患者を治療す る方法。 29.前記投与が非経口投与である、請求項28の方法。 30.前記投与が長期間連続投与である、請求項28の方法。 31.前記投与が植え込み可能な医薬送り出し器具の使用により行われる、請 求項28の方法。 32.前記症状が前立腺癌でありそして前記ペプチド化合物がロイプロリドで ある、請求項28の方法。 33.少なくとも約80ミクログラムのロイプロリドが毎日投与される、請求 項28の方法。 34.前記の毎日投与が3か月、6か月および12か月からなる群から選ばれ る期間続ける、請求項33の方法。 35.前記期間の前記毎日投与が植え込み可能な医薬送り出しシステムを用い て行われる連続投与である、請求項34の方法。 36.前記症状が前立腺癌でありそして前記ペプチド化合物がLHRHK拮抗 薬である、請求項28の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2112996P | 1996-07-03 | 1996-07-03 | |
US60/021,129 | 1996-07-03 | ||
PCT/US1997/010815 WO1998000152A1 (en) | 1996-07-03 | 1997-07-01 | Non-aqueous protic peptide formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008112307A Division JP2008195739A (ja) | 1996-07-03 | 2008-04-23 | 非水性プロトン性ペプチド配合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001504802A true JP2001504802A (ja) | 2001-04-10 |
Family
ID=21802501
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50421898A Withdrawn JP2001504802A (ja) | 1996-07-03 | 1997-07-01 | 非水性プロトン性ペプチド配合物 |
JP2008112307A Pending JP2008195739A (ja) | 1996-07-03 | 2008-04-23 | 非水性プロトン性ペプチド配合物 |
JP2009231256A Pending JP2010043105A (ja) | 1996-07-03 | 2009-10-05 | 非水性プロトン性ペプチド配合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008112307A Pending JP2008195739A (ja) | 1996-07-03 | 2008-04-23 | 非水性プロトン性ペプチド配合物 |
JP2009231256A Pending JP2010043105A (ja) | 1996-07-03 | 2009-10-05 | 非水性プロトン性ペプチド配合物 |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP0909175B1 (ja) |
JP (3) | JP2001504802A (ja) |
CN (1) | CN1231256C (ja) |
AR (1) | AR008060A1 (ja) |
AT (1) | ATE241997T1 (ja) |
AU (1) | AU737664B2 (ja) |
BR (1) | BR9710130A (ja) |
CA (1) | CA2259403A1 (ja) |
CO (1) | CO4890854A1 (ja) |
CZ (1) | CZ433898A3 (ja) |
DE (1) | DE69722620T2 (ja) |
DK (1) | DK0909175T3 (ja) |
ES (1) | ES2201306T3 (ja) |
HU (1) | HUP9903942A3 (ja) |
ID (1) | ID19165A (ja) |
IL (1) | IL127769A (ja) |
MY (1) | MY121684A (ja) |
NO (1) | NO323933B1 (ja) |
NZ (1) | NZ333580A (ja) |
PL (1) | PL189402B1 (ja) |
PT (1) | PT909175E (ja) |
RO (1) | RO119862B1 (ja) |
RU (1) | RU2203085C2 (ja) |
SK (1) | SK284490B6 (ja) |
TW (1) | TW491703B (ja) |
WO (1) | WO1998000152A1 (ja) |
ZA (1) | ZA975942B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524705A (ja) * | 2003-04-25 | 2006-11-02 | ボストン サイエンティフィック シメド インコーポレーテッド | 固形薬物製剤並びにそれらの貯蔵及び制御された放出のための装置 |
JP2011528373A (ja) * | 2008-07-16 | 2011-11-17 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 生理活性ペプチドを含有する微粒子を調製するためのプロセス |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9710130A (pt) * | 1996-07-03 | 1999-08-10 | Alza Corp | Formulações de peptídeos próticas não-aquosas |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US20030119734A1 (en) | 2001-06-28 | 2003-06-26 | Flink James M. | Stable formulation of modified GLP-1 |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
PT3300721T (pt) * | 2003-11-20 | 2019-06-06 | Novo Nordisk As | Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
ES2351527T3 (es) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración. |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
DK2121025T3 (en) * | 2007-01-19 | 2017-01-30 | Hananja Ehf | Methods and compositions for delivering a therapeutic agent |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
AU2013203271B2 (en) * | 2007-01-19 | 2016-05-12 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
DK2170283T3 (en) | 2007-06-22 | 2019-04-15 | Univ Texas | CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
JP5770629B2 (ja) | 2008-08-15 | 2015-08-26 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤 |
US8779094B2 (en) | 2008-11-16 | 2014-07-15 | Board Of Regents, The University Of Texas System | Low viscosity highly concentrated suspensions |
CA2770077A1 (en) | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
CN102869677B (zh) | 2010-02-17 | 2015-07-08 | 硬木药品公司 | 胃肠病症的治疗 |
SI2603232T1 (sl) | 2010-08-11 | 2020-03-31 | Ironwood Pharmaceuticals, Inc. | Stabilne formulacije linaklotida |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
MX347354B (es) | 2011-08-17 | 2017-04-24 | Ironwood Pharmaceuticals Inc | Tratamientos para trastornos gastrointestinales. |
US20130288968A1 (en) * | 2012-04-30 | 2013-10-31 | Sun Pharmaceutical Industries Ltd. | Leuprolide injection |
US9956287B2 (en) | 2013-02-06 | 2018-05-01 | Perosphere Inc. | Stable glucagon formulations |
EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MA44390A (fr) | 2015-06-03 | 2019-01-23 | Intarcia Therapeutics Inc | Systèmes de mise en place et de retrait d'implant |
SG11201810102SA (en) | 2016-05-16 | 2018-12-28 | Intarcia Therapeutics Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
EP3372224A1 (en) | 2017-03-07 | 2018-09-12 | Alrise Biosystems GmbH | New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles |
WO2019038412A1 (en) | 2017-08-24 | 2019-02-28 | Novo Nordisk A/S | GLP-1 COMPOSITIONS AND USES THEREOF |
AU2021207313A1 (en) | 2020-02-18 | 2022-07-28 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897256A (en) * | 1986-11-25 | 1990-01-30 | Abbott Laboratories | LHRH analog formulations |
JP2851627B2 (ja) * | 1987-10-15 | 1999-01-27 | シンテックス(ユー・エス・エイ)インコーポレイテッド | 粉末形態ポリプペチド類の経鼻投与 |
IT1237197B (it) * | 1989-11-16 | 1993-05-26 | Sclavo Spa | Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina. |
AU5018693A (en) * | 1992-09-21 | 1994-04-12 | Upjohn Company, The | Sustained-release protein formulations |
DE69426292T2 (de) * | 1993-02-23 | 2001-05-17 | Genentech Inc | Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff |
US5955430A (en) * | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
JP3597233B2 (ja) * | 1993-10-21 | 2004-12-02 | 久光製薬株式会社 | 経鼻組成物及びそれを含有する経鼻製剤 |
BR9710130A (pt) * | 1996-07-03 | 1999-08-10 | Alza Corp | Formulações de peptídeos próticas não-aquosas |
-
1997
- 1997-07-01 BR BR9710130A patent/BR9710130A/pt not_active Application Discontinuation
- 1997-07-01 HU HU9903942A patent/HUP9903942A3/hu unknown
- 1997-07-01 PL PL97330869A patent/PL189402B1/pl not_active IP Right Cessation
- 1997-07-01 WO PCT/US1997/010815 patent/WO1998000152A1/en not_active Application Discontinuation
- 1997-07-01 DE DE69722620T patent/DE69722620T2/de not_active Expired - Lifetime
- 1997-07-01 AT AT97930181T patent/ATE241997T1/de active
- 1997-07-01 SK SK1799-98A patent/SK284490B6/sk not_active IP Right Cessation
- 1997-07-01 CA CA002259403A patent/CA2259403A1/en not_active Abandoned
- 1997-07-01 EP EP97930181A patent/EP0909175B1/en not_active Expired - Lifetime
- 1997-07-01 PT PT97930181T patent/PT909175E/pt unknown
- 1997-07-01 ES ES97930181T patent/ES2201306T3/es not_active Expired - Lifetime
- 1997-07-01 CN CNB971960534A patent/CN1231256C/zh not_active Expired - Fee Related
- 1997-07-01 AU AU34073/97A patent/AU737664B2/en not_active Ceased
- 1997-07-01 CZ CZ984338A patent/CZ433898A3/cs unknown
- 1997-07-01 RO RO98-01769A patent/RO119862B1/ro unknown
- 1997-07-01 RU RU99102540/14A patent/RU2203085C2/ru not_active IP Right Cessation
- 1997-07-01 NZ NZ333580A patent/NZ333580A/en not_active IP Right Cessation
- 1997-07-01 IL IL127769A patent/IL127769A/en not_active IP Right Cessation
- 1997-07-01 DK DK97930181T patent/DK0909175T3/da active
- 1997-07-01 JP JP50421898A patent/JP2001504802A/ja not_active Withdrawn
- 1997-07-02 AR ARP970102967A patent/AR008060A1/es unknown
- 1997-07-03 CO CO97037097A patent/CO4890854A1/es unknown
- 1997-07-03 MY MYPI97003024A patent/MY121684A/en unknown
- 1997-07-03 ID IDP972315A patent/ID19165A/id unknown
- 1997-07-03 ZA ZA9705942A patent/ZA975942B/xx unknown
- 1997-08-22 TW TW086109392A patent/TW491703B/zh not_active IP Right Cessation
-
1998
- 1998-12-30 NO NO19986209A patent/NO323933B1/no not_active IP Right Cessation
-
2008
- 2008-04-23 JP JP2008112307A patent/JP2008195739A/ja active Pending
-
2009
- 2009-10-05 JP JP2009231256A patent/JP2010043105A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524705A (ja) * | 2003-04-25 | 2006-11-02 | ボストン サイエンティフィック シメド インコーポレーテッド | 固形薬物製剤並びにそれらの貯蔵及び制御された放出のための装置 |
JP4734236B2 (ja) * | 2003-04-25 | 2011-07-27 | ボストン サイエンティフィック サイムド,インコーポレイテッド | 固形型の薬物の貯蔵及び制御された放出のための装置及びその製造方法 |
JP2011528373A (ja) * | 2008-07-16 | 2011-11-17 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 生理活性ペプチドを含有する微粒子を調製するためのプロセス |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001504802A (ja) | 非水性プロトン性ペプチド配合物 | |
JP2001504442A (ja) | ペプチド類の水性配合物 | |
RU2203084C2 (ru) | Стабильный неводный препарат пептидного соединения (варианты), способ его получения (варианты) и способ лечения гормон-зависимого заболевания у субъекта (варианты) | |
US5981489A (en) | Non-aqueous protic peptide formulations | |
KR100594519B1 (ko) | 비수성양성자성펩티드제제 | |
AU2004242540B2 (en) | Aqueous formulations of peptides | |
AU775395B2 (en) | Non-aqueous polar aprotic peptide formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070626 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071114 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080327 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080512 |